Therapeutic resistance and hematological tumors
Sureda’s & Farre’s Lab

DESCRIPTION

Our group aims to gain a better understanding of the clinical characteristics and mechanisms of progression and therapeutic resistance of hematological tumors with a focus on multiple myeloma and aggressive T and B lymphomas to propose new therapeutic strategies.

The lab is interested in improving the understanding of the molecular mechanisms leading to the progression and therapeutic resistance of multiple myeloma, including extramedullary disease, Hodgkin lymphoma and aggressive non-Hodgkin B and T lymphomas.

To develop these lines of research, we use patient samples and advanced preclinical models for therapeutic, mechanistic and functional studies. We have developed the technology to generate murine models derived from patients by orthotopic implantation (orthotopic PDX) and 2D/3D cultures that we can humanize using components of the human immune system (from the same patient from whom the model has been derived, when possible). Additionally, we are involved in a project that is developing humanized nanomedicines as a new therapeutic strategy for acute myeloid leukemia.

Our group is integrated by professionals from the Clinical Hematology Service of ICO/Hospitalet, the ProCURE/ICO Program and the Pathology Service of the Hospital of Bellvitge. Within the Hematology Service of the ICO Hospitalet, one of our main objectives is to promote translational research training for the professionals of the Service, generating opportunities for the completion of doctoral theses and stimulating new scientific leadership as well as to attract talent with a mixed clinical/researcher profile for the Service.

Posdoctoral researcher

Publications

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes

15 de September de 2007/in Sureda's & Farre's Lab/by

Br J Haematol. 2007 Oct;139(1):70-80. doi: 10.1111/j.1365-2141.2007.06759.x. ABSTRACT The introduction of reduced-intensity conditioning (RIC) has enabled the role of allogeneic transplantation to be re-evaluated in Hodgkin lymphoma (HL). While T-cell depletion reduces graft-versus-host disease (GvHD), it potentially abrogates graft-versus-tumour activity and increases infective complications. We compared the results in 67 sibling donor transplantations following RIC […]

Adult T-cell leukemia/lymphoma with a mixed CD4+ and CD8+ phenotype and indolent course

15 de June de 2007/in Sureda's & Farre's Lab/by miguel

J Clin Oncol. 2007 Jun 10;25(17):2480-2. doi: 10.1200/JCO.2007.11.3043. NO ABSTRACT PMID:17557960 | DOI:10.1200/JCO.2007.11.3043

Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas

15 de December de 2005/in Sureda's & Farre's Lab/by miguel

Int J Cancer. 2006 May 15;118(10):2381-9. doi: 10.1002/ijc.21662. ABSTRACT Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is effective as chemopreventive against colon cancer and it is the only nonsteoroidal antiinflammatory drug approved by the FDA for adjuvant therapy in patients with familial adenomatous polyposis. It is also being evaluated, within Phase II and III clinical trials, […]

Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin’s disease: indications and results

19 de February de 2004/in Sureda's & Farre's Lab/by

Semin Oncol. 2004 Feb;31(1):27-32. doi: 10.1053/j.seminoncol.2003.10.018. ABSTRACT A number of treatment options are available for patients with relapsed Hodgkin’s disease (HD). Radiotherapy, salvage chemotherapy, high-dose therapy (HDT) followed by autologous transplantation, and classical or nonmyeloablative conditioning followed by allogeneic transplantation can all be effective in patients with relapsed HD. Patients with early relapse after modern […]

Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation

26 de March de 2003/in Sureda's & Farre's Lab/by

Haematologica. 2003 Mar;88(3):300-5. ABSTRACT BACKGROUND AND OBJECTIVES: Patients over 60 years are frequently excluded from autologous stem cell transplantation (ASCT) programs due to a traditionally high rate of transplant-related mortality (TRM) in such indications. We evaluated the results of ASCT in a group of 49 patients >= 60 years of age [32 males, median age […]

Research Projects

PI21/00684. Improving Outcomes of Patients with Extramedullary Multiple Myeloma. Potential Applicability of Orthoxenograft Models in the Study of Genetic Bases of Drug Resistance. ISCIII/AES. Budget: 135.520,00 euros, 2022 – 2024. PI: Anna Sureda, Co-PI: Lourdes Farre.

201941-30. Humanized nanomedicines selectively killing CXCR4+ cancer cells for Acute Myeloid Leukemia therapy. Marató TV3. Budget: 99.960,81 euros, 2020 – 2024. Projecte coordinat. Sub-projecte PI: Dra. Lourdes Farre

Collaborations

Isolda Casanova. Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Toni Villaverde. Institut de Biotecnologia i de Biomedicina. Universitat Autònoma de Barcelona, Bellaterra, Spain

Sonia Guil. Josep Carreras Leukaemia Research Institute, Badalona, Spain.

Therapeutic resistance and hematological tumorsSureda’s & Farre’s Lab

DESCRIPTION

Lourdes Farre

Group leaders

Anna Sureda

Group leaders

Eva Domingo

Principal Researcher

Eva González-Barca

Principal Researcher

Fina Climent

Principal Researcher

Itziar Carro

Clinical researcher

Anna Bosch

Clinical researcher

Cristina Baca

Clinical researcher

Abel Domingo

Clinical researcher

Laia Ferrer

Young investigators

Juan Francisco Martin Tejera

Young investigators

CONTACT US

Therapeutic resistance and hematological tumors
Sureda’s & Farre’s Lab